Evidence map›Paper›PMID 42798467›Full record

ArticleFrontiers in artificial intelligence2026

A two-stage deep learning framework with progressive feature fusion and attention mechanisms for multi-class retinal disease classification.

Mithun Vijayan, Goutham Veerapu, Nisha J S

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mithun VijayanSchool of Electronics Engineering, Vellore Institute of Technology, Vellore, India.
Goutham VeerapuSchool of Electronics Engineering, Vellore Institute of Technology, Vellore, India.
Nisha J SComputer Science Engineering, Indian Institute of Information Technology, Kottayam, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate and efficient automated analysis of Optical Coherence Tomography (OCT) images is critical for large-scale retinal disease screening. However, current deep learning models often fail to simultaneously achieve high classification accuracy, practical computational feasibility, and interpretability. To deal with these problems, this paper presents a deep learning framework on YOLOv11 for eight-class retinal disease classification optimized using a two-stage optimization strategy. The proposed architecture incorporates a Progressive Spatial Fusion (PSF) module to hierarchically integrate multi-scale feature representations, followed by a Squeeze-and-Excitation (SE)-based dual-attention refinement mechanism that refines disease-discriminative features prior to classification. Evaluated on the OCT-C8 dataset, the proposed model achieves 98.00% accuracy, precision, recall, and F1-score, together with 99.70% specificity, while achieving perfect classification performance for the Age-related Macular Degeneration (AMD), Central Serous Retinopathy (CSR), Diabetic Retinopathy (DR), and Macular Hole (MH) classes. Grad-CAM visualizations provide qualitative insights into image regions influencing model predictions and show correspondence with disease-associated structural patterns reported in OCT literature. These results show that the proposed framework provides a good trade-off between classification performance, computational requirements and interpretability and shows potential for automated OCT-based retinal disease screening support.

Indexed as

attention mechanismdeep learningGrad-CAMimage classificationophthalmologyoptical coherence tomographyretinal diseasesYOLOv11

Identifiers

PMID42798467
PMCPMC13612441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.